Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEVANTE study of inhaled AZD8630 in uncontrolled asthma
2024-514228-18-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing AZD8630 dose arm(s) with Placebo (2 arms). Primary endpoint: Time to first CompEx Asthma event. Started Dec 2024; status: completed.
02
Drugs
azd8630
03
Conditions
asthma
Beyond the preview
Go deeper on 2024-514228-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514228-18-00.